Clinical trials
Observational Sarcopenia trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
21 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2012 | 1 |
| 2019 | 4 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 8 |
| Unknown status | 7 |
| Recruiting | 3 |
| Enrolling by invitation | 1 |
| Not yet recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Salamanca | 2 |
| Camilo Jose Cela University | 1 |
| Catholic University of Murcia | 1 |
| Felipe León Morillas | 1 |
| Fundacin Biomedica Galicia Sur | 1 |
| Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | 1 |
| Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz | 1 |
| Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 1 |
| Hospital Clinic of Barcelona | 1 |
| Hospital Mutua de Terrassa | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sarcopenia | 21 |
| Frailty | 5 |
| Malnutrition | 4 |
| Critical Illness | 2 |
| Disease | 2 |
| Obesity | 2 |
| Anxiety Disorders | 1 |
| COVID-19 | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Deglutition Disorders | 1 |
Trials
Showing 1 to 21 of 21. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.